Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

Half Year Results/Half Year ReportFormycon confirms full-year guidance following business development in line with plan – working capital raised 13.08.2025 / 06:30 CET/CESTThe issuer is solely ...

Senores Pharmaceuticals rose 2.16% to Rs 687.75 after its US arm signed a deal to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA, targeting a market size of up to $120 million.

Teva Pharmaceutical Industries (NYSE:TEVA) shares continued gains for seven straight sessions, as the stock closed 1% higher ...

The FDA has approved Ajovy for migraine prevention in children and teens, marking the first time a medication in its class is cleared for pediatric use.

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

Calling to stop using toxic and carcinogenic materials in kindergartens, schools and parks, organizations cite research, note ...

UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics.

PureTech Health announced the launch of Celea Therapeutics on Tuesday, a new company focused on developing treatments for ...

PureTech has promoted Sven Dethlefs, who has been involved in the drug's development over the past year, to lead Celea. Dethlefs is the ex-chief executive of North America at Teva Pharmaceuticals ...

PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases ...